Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
CancerGastrointestinal Cancer
Interventions
GENETIC

"Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx"

Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.

Trial Locations (1)

28204

RECRUITING

Atrium Health Levine Cancer, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER

NCT06489041 - Evaluating Microarray Pharmacogenetic Testing in Cancer Patients | Biotech Hunter | Biotech Hunter